Fostamatinib (R788) 化学構造
分子量: 580.46

高品質保証

カスタマーフィードバック(1)

MSDS

製品説明

  • Compare Syk Inhibitors
    Syk製品生物活性の比較
  • 研究分野

製品の説明

生物活性

製品説明 Fostamatinib (R788)は、<b>Syk</b> 阻害剤で、 IC50 が41 nMです。
ターゲット

Syk

Adenosine A3 receptor

Adenosine transporter

Monoamine transporter

IC50

41 nM

81 nM

1.84 μM

2.74 μM [1]

In vitro試験 R788 is a prodrug of the spleen tyrosine kinase (Syk) inhibitor R406. R788 is a competitive inhibitor for ATP binding with a Ki of 30 nM. R788 dose-dependently inhibits anti-IgE-mediated CHMC degranulation with an EC50 of 56 nM. R788 also inhibits the anti-IgE-induced production and release of LTC4 and cytokines and chemokines, including TNFα, IL-8, and GM-CSF. Inhibition of Syk by R788 results in inhibition of all phosphorylation events downstream of Syk signaling. Next to FcϵRI signaling in CHMC, R788 most potently inhibits the signaling of IL-4 and IL-2 receptors. R788 specifically inhibits FcγR signaling in human mast cells, macrophages, and neutrophils. R788 can inhibit local inflammatory injury mediated by immune complexes. [1] R788 induces apoptosis of the majority of examined DLBCL cell lines. In R788-sensitive DLBCL cell lines, R788 specifically inhibits both tonic- and ligand-induced BCR signaling (autophosphorylation of SYK525/526 and SYK-dependent phosphorylation of the B-cell linker protein [BLNK]). [2]
In vivo試験 Oral administration of R788 to mice reduces immune complex-mediated inflammation in a reverse-passive Arthus reaction and two antibody-induced arthritis models. [1] In another study, R788 effectively inhibits BCR signaling in vivo, resulting in reduced proliferation and survival of the malignant B cells and significantly prolongs survival of the treated animals. [3] R788 demonstrates a significant reduction in major inflammatory mediators such as TNFalpha, IL-1, IL-6 and IL-18, leading to reduced inflammation and bone degradation in models of rheumatoid arthritis. [4]
臨床試験 R788 has entered in a phase III clinical trial in the treatment of rheumatoid arthritis.
特集 Converted into its active metabolite R406 in vivo.

プロトコル (参考用のみ)

キナーゼアッセイ:

[1]

Fluorescence polarization kinase assay and Ki determination The fluorescence polarization reactions are performed. For Ki determination, duplicate 200-μL reactions are set up at eight different ATP concentrations from 200 μM (2-fold serial dilutions) in the presence of either DMSO or R788 at 125, 62.5, 31.25, 15.5, or 7.8 nM. At different time points, 20 μL of each reaction is removed and quenched to stop the reaction. For each concentration of R788, the rate of reaction at each concentration of ATP is determined and plotted against the ATP concentration to determine the apparent Km and Vmax (maximal rate). Finally the apparent Km (or apparent Ki/Vmax) is plotted against the inhibitor concentration to determine the Ki.

細胞アッセイ:

[1]

細胞株 Cultured human mast cells (CHMC)
濃度 0 μM -100 μM
反応時間 30 minutes
実験の流れ

Cultured human mast cells (CHMC) are derived from cord blood CD34+ progenitor cells and grown, primed, and stimulated and shown in supplemental data. Before stimulation, cells are incubated with R788 or DMSO for 30 minutes. Cells are then stimulated with either 0.25 to 2 mg/mL anti-IgE or anti-IgG or 2 μM ionomycin. For tryptase measurement, ∼1500 cells per well are stimulated for 30 min in modified Tyrode's buffer. For LTC4 and cytokine production, 100,000 cells per well are stimulated for 1 or 7 hours, respectively. Tryptase activity is measured by luminescence readout of a peptide substrate, and LTC4 and cytokines are measured using Luminex multiplex technology.

動物実験:

[1]

動物モデル Balb/c mice with arthritis
製剤 35% TPGS, 60% PEG 400, 5% propylene glycol
投薬量 1 mg/kg or 5 mg/kg
投与方法 Orally b.i.d

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download Fostamatinib (R788) SDF
分子量 580.46
化学式

C23H26FN6O9P

CAS No. 901119-35-5
保管 3年-20℃
2年-80℃in solvent
別名 N/A
溶解度 (25°C) * In vitro DMSO 116 mg/mL (199.84 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 4% DMSO+30% PEG 300+ddH2O 5mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 (6-(5-fluoro-2-(3,4,5-trimethoxyphenylamino)pyrimidin-4-ylamino)-2,2-dimethyl-3-oxo-2,3-dihydropyrido[3,2-b][1,4]oxazin-4-yl)methyl dihydrogen phosphate

文献中の引用 (2)

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related Syk 阻害剤

  • PX-478 2HCl

    PX-478 2HCl is an orally active, and selective hypoxia-inducible factor-1α (HIF-1α) inhibitor. Phase 1.

  • Defactinib (VS-6063, PF-04554878)

    Defactinib (VS-6063, PF-04554878) is a selective, and orally active FAK inhibitor. Phase 2.

  • SU6656

    SU 6656 is a selective Src family kinase inhibitor with IC50 of 280 nM, 20 nM, 130 nM, and 170 nM for Src, Yes, Lyn, and Fyn, respectively.

  • Dasatinib Monohydrate

    Dasatinib Monohydrate is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM, respectively.

  • R406 (free base)

    R406 (free base)(フリーベース)は、脾臓チロシン・キナーゼ(Syk)阻害剤で、 IC50 が 41 nMになる。

  • R406

    R406は、強力な脾臓チロシン・キナーゼ(Syk)阻害剤で、EC50 と Ki がそれぞれ 56 nM と 30 nMです。

    Features:Lead drug candidate for rheumatoid arthritis.

  • R788 (Fostamatinib) Disodium

    R788 (Fostamatinib) Disodiumは、41nMのIC50による選択的な脾臓Syk阻害剤です。

    Features:Clinically used oral formulation of R406.

  • Piceatannol

    Piceatannolは、~10μMのIC50による選択的なSyk阻害剤です。

  • PRT062607 (P505-15, BIIB057) HCl

    PRT062607 (P505-15, BIIB057) HClは、新しい、非常に選択的なSyk阻害剤で、IC50 が 1 nMです。

最近チェックしたアイテム

Tags: Fostamatinib (R788)を買う | Fostamatinib (R788)供給者 | Fostamatinib (R788)を購入する | Fostamatinib (R788)費用 | Fostamatinib (R788)生産者 | オーダーFostamatinib (R788) | Fostamatinib (R788)代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ